GHRP-2

A growth hormone secretagogue is any compound that makes the pituitary gland release its own stored growth hormone (GH), rather than supplying GH from outside the body. That distinction matters more than it sounds. Recombinant human growth hormone floods the circulation with hormone on a schedule set by the injection. A secretagogue works upstream: it nudges a gland that still has its own feedback loops, its own pulse generator, and its own ceiling.

The family splits into two branches that act through completely different receptors. The first branch mimics growth hormone releasing hormone (GHRH), the hypothalamic peptide that normally instructs somatotroph cells to secrete. Sermorelin, tesamorelin and CJC-1295 belong here. The second branch mimics ghrelin, the stomach-derived hormone discovered after its receptor, and acts on GHS-R1a, the growth hormone secretagogue receptor type 1a. GHRP-2 sits squarely in this second branch, along with GHRP-6, hexarelin and ipamorelin.

The history is unusual because the drugs came first. Cyril Bowers and colleagues built synthetic peptides that released GH through a pathway nobody could identify, and only later did the receptor get cloned from pituitary and hypothalamic tissue, confirming that a distinct GH-releasing receptor existed separate from the GHRH receptor. The endogenous ligand, ghrelin, was identified afterwards. GHRP-2 is therefore best understood as a laboratory molecule that turned out to have a natural counterpart, not the other way around.

Within the ghrelin-receptor branch, GHRP-2 occupies a particular position. It was designed as a structural refinement of the earlier GHRP-6, and for roughly a decade it was the compound clinical endocrinology took most seriously as a diagnostic tool. It is also the pivot point for anyone trying to understand the whole class, because almost every comparison a reader makes (GHRP-6, hexarelin, ipamorelin) is a comparison against GHRP-2.

Educational note: this guide describes published research. It is not medical advice, recommends no dose or protocol, and none of these compounds is approved as a therapy in the United States or the European Union. Consult a qualified healthcare professional before considering anything discussed here.

GHRP-2 is a six amino acid peptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, molecular formula C₄₅H₅₅N₉O₆ and a molecular weight near 818 g/mol. Several of its residues are in the D configuration, and the C-terminus is amidated. Both features are there for the same reason: natural L-amino acid peptides of this size are degraded within minutes by circulating peptidases, and the unnatural residues slow that process enough for the molecule to reach the pituitary intact.

Mechanistically, GHRP-2 is an agonist at GHS-R1a. This is a G protein-coupled receptor expressed in the anterior pituitary and in the arcuate nucleus of the hypothalamus, cloned in the mid-1990s precisely because synthetic GH releasing peptides were known to act somewhere that GHRH did not. Activation triggers a phospholipase C and inositol trisphosphate cascade, raises intracellular calcium in somatotroph cells, and produces exocytosis of stored growth hormone. Because the pathway differs from the cyclic AMP pathway used by the GHRH receptor, the two stimuli are additive rather than redundant, which is the pharmacological basis for the pairings discussed later in this guide.

The second half of the mechanism is often skipped. GHS-R1a activation in the hypothalamus also reduces the release of somatostatin, the brake on GH secretion. So a GHRP produces GH output through two levers at once: it presses the accelerator at the pituitary and releases the brake at the hypothalamus. This is part of why these peptides can generate larger GH peaks than a GHRH analogue alone.

Kinetically, GHRP-2 is a short-acting compound. Growth hormone rises quickly after intravenous administration, peaks within roughly the first half hour, and falls back toward baseline over the following hours. This profile is exactly what makes GHRP-2 useful as a diagnostic stimulus: a single dose, a handful of timed blood draws, and a clear peak value to interpret. It is also the property that shapes how people who use these peptides outside medicine structure their schedules, since the pulse is brief by design.

One consequence of the ghrelin-receptor mechanism deserves emphasis. GHS-R1a is not a GH-only receptor. The same receptor family mediates appetite signalling and interacts with the hypothalamic-pituitary-adrenal axis, which is why GHRP-2 affects hunger, prolactin and cortisol as well as growth hormone. That lack of selectivity is not a manufacturing impurity or a dosing artifact. It is built into the target.

GHRP-2 has a regulatory footnote that no other member of its family shares. Under the international non-proprietary name pralmorelin, it was approved in Japan in 2004 as a diagnostic agent for growth hormone deficiency, marketed by Kaken Pharmaceutical. The approval rests on a simple clinical logic: a single intravenous dose provokes a GH peak in a patient with an intact somatotroph population, and a blunted or absent peak supports a diagnosis of deficiency. It is a one-dose test, administered in a clinical setting, with a measured endpoint.

What that approval is not is an endorsement of GHRP-2 as a therapy. Japan did not approve it for growth promotion, body composition, recovery, sleep or anti-aging. No regulator anywhere has. The US Food and Drug Administration and the European Medicines Agency have approved no growth hormone releasing peptide for any therapeutic indication, and in the United States GHRP-2 falls outside the compounding pathways available to licensed pharmacies. Legal status varies by jurisdiction and changes, so readers should check their own country's current rules rather than assume.

For athletes, the position is unambiguous. The World Anti-Doping Agency Prohibited List covers this class under section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. Within the growth hormone releasing factors subsection, the List names GH-releasing peptides (GHRPs) with explicit examples including GHRP-2 (pralmorelin), examorelin (hexarelin) and GHRP-6, alongside a separate group of GH secretagogues and mimetics that names ipamorelin, anamorelin, macimorelin and ibutamoren. GHRH analogues including CJC-1295, sermorelin and tesamorelin appear in the same section. S2 substances are prohibited at all times, meaning both in competition and out of competition.

Detection is not theoretical either. Validated liquid chromatography tandem mass spectrometry methods for pralmorelin and its urinary metabolite have been published in the anti-doping literature, and the class is routinely screened. The practical summary for a competing athlete is that GHRP-2 is a banned substance with an established analytical method behind it.

A final commercial note for readers: this site lists no GHRP-2, GHRP-6 or hexarelin product, and no purchase link for any of them is offered here. Where these peptides are sold, they are sold as research chemicals not intended for human use, and product identity and purity are not verified by any regulator.

This is the question most readers arrive with, and the honest answer is that the four molecules share one receptor and differ mainly in how cleanly and how durably they hit it. All four are GHS-R1a agonists. None of them introduces a new mechanism of growth hormone release. What separates them is the size of the collateral signalling, the speed at which the receptor response fades, and how much human data exists.

GHRP-2. The best documented of the four in humans. In a direct comparison in healthy volunteers, GHRP-2 produced a GH response higher than GHRH, and the effect was both dose-dependent and age-dependent, with older subjects responding less. The same study found that GHRP-2's activity was not specific: it raised prolactin, ACTH and cortisol, with the prolactin rise smaller than that produced by TRH but the ACTH and cortisol rise comparable to that produced by human CRH. That last comparison is the single most useful fact in this guide, because it quantifies the cortisol issue against a reference stimulus rather than leaving it as a vague warning.

GHRP-6. The original of the group and the molecule GHRP-2 was engineered to improve on. The folk wisdom is that GHRP-6 causes intense hunger while GHRP-2 releases more GH with less appetite stimulation. The first half is well supported. The second half needs qualifying: healthy men receiving a subcutaneous GHRP-2 infusion ate 35.9 percent more at a buffet meal than on saline, and every subject in the study increased intake. GHRP-2 is not an appetite-neutral peptide. It is plausibly less hunger-driving than GHRP-6, but the rigorous head-to-head appetite comparison in humans that would settle it has not been published. Laboratory work in rat pituitary cells also showed that the two peptides cross-desensitize each other while leaving the GHRH response intact, confirming they compete at the same site.

Hexarelin. On paper the most potent, and the one with the most interesting side story. Beyond GHS-R1a, hexarelin binds CD36, a scavenger receptor expressed on cardiomyocytes and microvascular endothelial cells. In rat cardiac membranes, a radiolabeled hexarelin derivative identified an 84 kDa binding protein that proved to be CD36, and hexarelin raised coronary perfusion pressure in perfused hearts in a dose-dependent way. That effect disappeared in hearts from CD36-null mice and from rats genetically deficient in CD36, which is strong evidence that the cardiac action runs through CD36 rather than the ghrelin receptor, and therefore independently of growth hormone. This cardioprotection evidence is preclinical only. It comes from isolated hearts, knockout mice and rat models. No published human trial has tested hexarelin for cardioprotection, and nothing in this literature supports using it for a cardiac indication. Hexarelin also carries the clearest desensitization signal of the group: over 16 weeks of twice-daily subcutaneous administration in humans, the area under the GH curve fell progressively from baseline, with significant reductions at weeks 4 and 16, and recovered to near baseline four weeks after treatment stopped. The attenuation was partial and reversible, but it was real.

Ipamorelin. The molecule that quietly retired the older GHRPs. Ipamorelin is a pentapeptide developed specifically to separate GH release from the rest of the ghrelin receptor's output, and in its original characterization it did exactly that: GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol, while ipamorelin did not raise either above the levels seen after GHRH stimulation. The authors described it as the first selective growth hormone secretagogue, and that selectivity is the reason ipamorelin, not GHRP-2, is the peptide most people encounter today. Its own evidence base has limits worth understanding before drawing conclusions, which is why it has a dedicated page: see the ipamorelin guide rather than a summary here.

Pairing a GHRP with a GHRH analogue is the single most common arrangement in this space, and unlike a lot of stacking folklore, it has a coherent pharmacological rationale. The two compounds act on different receptors through different intracellular pathways. A GHRH analogue binds the GHRH receptor and works largely through cyclic AMP. A GHRP binds GHS-R1a and works through phospholipase C and calcium, while simultaneously reducing somatostatin tone in the hypothalamus.

The result is that the two stimuli are complementary rather than duplicative. The GHRH signal tells the somatotroph to secrete. The GHRP signal both amplifies that instruction and removes the inhibitory brake that would otherwise cap it. In endocrine testing, combined GHRH and GHRP stimulation has long been recognized as a more powerful provocative stimulus than either alone, which is the origin of the whole idea.

In practice this is why CJC-1295 appears next to a GHRP so often, and why the CJC-1295 and ipamorelin combination became the default pairing once ipamorelin's cleaner side effect profile became widely known. Other GHRH analogues exist with different pharmacokinetics: sermorelin is the short-acting original, and tesamorelin is the one that actually carries an approved indication, for HIV-associated lipodystrophy.

Two cautions belong with this rationale. First, a stronger GH pulse is not automatically a better outcome. The endpoints that matter clinically (body composition, recovery, metabolic markers, quality of life) have not been demonstrated for these combinations in adequately powered human trials, and a larger peak on a lab printout is a surrogate, not a result. Second, combining two secretagogues does nothing to address the non-GH effects of the GHRP component. Adding a GHRH analogue to GHRP-2 does not cancel the prolactin, ACTH or cortisol response; it simply adds a second GH stimulus alongside it.

The reported adverse effects of GHRP-2 follow directly from its receptor pharmacology, which makes them fairly predictable in kind, if not in magnitude.

• Cortisol and ACTH elevation. The best characterized non-GH effect. In healthy adults, GHRP-2 produced an ACTH and cortisol response comparable to that of human CRH within the same study protocol. Repeated activation of the HPA axis is not a trivial consideration, and it is the main reason this generation of peptides fell out of favor.
• Prolactin elevation. Also documented for GHRP-2 and hexarelin in the same human comparison, with the magnitude smaller than the response to TRH but clearly above baseline.
• Increased appetite and food intake. Measured directly rather than inferred: subcutaneous GHRP-2 infusion increased buffet meal intake by 35.9 percent versus saline in healthy men. Long-term oral GHRP-2 in growth hormone deficient children was likewise studied specifically for its effects on appetite and body weight.
• Tachyphylaxis with repeated exposure. Best documented for hexarelin, where the GH response fell progressively over 16 weeks of twice-daily dosing before recovering after a four week washout. Rat pituitary cell work showed GHRPs also cross-desensitize each other, so rotating between GHRP-2 and GHRP-6 is unlikely to reset the response.
• Glucose and insulin sensitivity. Growth hormone is a counter-regulatory hormone with anti-insulin effects, so any sustained increase in GH exposure carries a theoretical risk to glucose handling. This has not been well characterized for GHRP-2 specifically.
• Injection site reactions, water retention, transient flushing and headache are commonly described in user reports, but these come from uncontrolled settings rather than published trials and should be weighted accordingly.

There is also a category of risk that has nothing to do with pharmacology. Because no GHRP-2 product is approved or regulated as a medicine in the United States or Europe, what is in a given vial is unverified. Identity, purity, sterility, endotoxin content and actual peptide content per vial are all unknown outside of a certificate of analysis that the buyer cannot independently confirm. For a broader treatment of how to think about this category of risk, see are peptides safe.

A note on who should not consider this class at all: anyone with an active or suspected malignancy, given that growth hormone and IGF-1 are growth-promoting signals, and anyone with untreated endocrine disease. These are questions for a physician, not for an article.

Everything in this class is short-acting and pulse-based, which means the pattern of exposure over days and weeks matters more than any single administration. The desensitization data make this concrete: the hexarelin study showed a GH response that declined over months and then recovered after a washout, which is a pattern nobody would notice from a single measurement.

That is the practical argument for keeping structured records rather than relying on memory. The variables worth tracking are reconstitution date and concentration, the timing pattern of each pulse relative to meals and sleep, total duration of exposure, any washout periods, and objective markers ordered and interpreted by a clinician (IGF-1, fasting glucose, prolactin and morning cortisol are the obvious candidates given the pharmacology described above).

For the arithmetic side of this, we maintain dedicated tools: the GHRP-2 calculator, the GHRP-6 calculator and the hexarelin calculator. These handle reconstitution mathematics and record keeping. They do not recommend a dose, a frequency or a protocol, and they are not a substitute for medical supervision. This guide states no dose for any compound discussed, by design.

If you want reconstitution math and cycle tracking in one place, the Peptide Lab app brings the calculators and the tracker together.

It is worth being explicit about the size of the gap between what this class is marketed on and what has actually been demonstrated.

No therapeutic endpoint has been established. GHRP-2's one regulatory approval is for a single-dose diagnostic test. There is no approved therapeutic indication anywhere in the world, and the trials that would be needed to create one (adequately powered, controlled, with clinical rather than hormonal endpoints) have not been run. Everything claimed about body composition, recovery, sleep quality or aging rests on mechanism and extrapolation, not on outcome data.

Long-term safety is uncharacterized. The human studies that exist are short, small, and mostly focused on the acute hormonal response or on pediatric growth hormone deficiency. What repeated HPA axis activation over months or years does in an otherwise healthy adult has not been studied. Neither has the metabolic consequence of sustained intermittent GH elevation in people whose GH axis was normal to begin with.

The GHRP-2 versus GHRP-6 appetite difference is under-evidenced. It is repeated everywhere as settled fact. In reality, GHRP-2's own appetite effect has been measured and is substantial, and the controlled head-to-head comparison that would rank the two has not been published.

Hexarelin's cardiac story stops at the lab bench. The CD36 mechanism is well characterized in rodent and knockout models, and it is genuinely interesting biology. It has never been tested as a cardioprotective intervention in a published human trial. Treating a receptor-level finding in perfused rat hearts as a clinical property is exactly the kind of leap that makes this field hard to read honestly.

Desensitization kinetics differ by molecule and are only partly mapped. Hexarelin has the clearest human data. GHRP-2's own time course under chronic exposure, and ipamorelin's, are far less well described, which means any claim about optimal cycling patterns is inference rather than evidence.

Medical disclaimer: this article is for educational purposes only. It does not constitute medical advice, does not recommend any dose or protocol, and should not be used to guide decisions about your health. GHRP-2, GHRP-6 and hexarelin are not approved for human therapeutic use in the United States or the European Union, their legal status varies by jurisdiction, and much of the evidence cited here is preclinical. Consult a qualified healthcare professional before acting on anything you read here.